Trade Cortexyme, Inc. - CRTX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0344 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 0.54-7.28 |
Average Volume (10 days) | 6.92M |
Average Volume (3 months) | 27.45M |
Market Cap | 36.13M |
P/E Ratio | -100.00K |
Shares Outstanding | 36.13M |
Revenue | N/A |
EPS | -2.23 |
Dividend (Yield %) | N/A |
Beta | 1.27 |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 23, 2023 | 0.7263 | 0.0000 | 0.00% | 0.7263 | 0.7263 | 0.7263 |
Jan 10, 2023 | 0.7263 | 0.0000 | 0.00% | 0.7263 | 0.7263 | 0.7263 |
Dec 28, 2022 | 0.7263 | 0.0000 | 0.00% | 0.7263 | 0.7263 | 0.7263 |
Dec 13, 2022 | 0.7263 | 0.0000 | 0.00% | 0.7263 | 0.7263 | 0.7263 |
Nov 30, 2022 | 0.7263 | 0.0720 | 11.00% | 0.6543 | 0.7263 | 0.6543 |
Nov 29, 2022 | 0.6608 | -0.0270 | -3.93% | 0.6878 | 0.7013 | 0.6453 |
Nov 28, 2022 | 0.6973 | 0.0296 | 4.43% | 0.6677 | 0.6973 | 0.6577 |
Nov 25, 2022 | 0.7093 | -0.0022 | -0.31% | 0.7115 | 0.7155 | 0.7015 |
Nov 23, 2022 | 0.7189 | 0.0116 | 1.64% | 0.7073 | 0.7189 | 0.6968 |
Nov 22, 2022 | 0.7293 | 0.0420 | 6.11% | 0.6873 | 0.7436 | 0.6793 |
Nov 21, 2022 | 0.6993 | -0.0250 | -3.45% | 0.7243 | 0.7343 | 0.6893 |
Nov 18, 2022 | 0.7243 | 0.0149 | 2.10% | 0.7094 | 0.7243 | 0.6993 |
Nov 17, 2022 | 0.6893 | -0.0080 | -1.15% | 0.6973 | 0.7093 | 0.6593 |
Nov 15, 2022 | 0.7493 | 0.0002 | 0.03% | 0.7491 | 0.7659 | 0.7009 |
Nov 14, 2022 | 0.6723 | -0.0969 | -12.60% | 0.7692 | 0.7692 | 0.6701 |
Nov 11, 2022 | 0.8065 | 0.0982 | 13.86% | 0.7083 | 0.8293 | 0.7083 |
Nov 10, 2022 | 0.7442 | 0.0099 | 1.35% | 0.7343 | 0.7615 | 0.7243 |
Nov 9, 2022 | 0.7213 | -0.0875 | -10.82% | 0.8088 | 0.8092 | 0.7043 |
Nov 8, 2022 | 0.7992 | -0.0400 | -4.77% | 0.8392 | 0.8393 | 0.7792 |
Nov 7, 2022 | 0.8582 | 0.0290 | 3.50% | 0.8292 | 0.8691 | 0.8192 |
Cortexyme, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 10.37 | 12.119 | 39.168 | 78.893 | 90.318 |
Selling/General/Admin. Expenses, Total | 1.271 | 2.034 | 8.954 | 17.586 | 29.523 |
Research & Development | 9.099 | 10.085 | 30.214 | 61.307 | 60.795 |
Operating Income | -10.37 | -12.119 | -39.168 | -78.893 | -90.318 |
Interest Income (Expense), Net Non-Operating | -1.865 | -0.357 | 2.188 | 2.044 | 0.62 |
Net Income Before Taxes | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Net Income After Taxes | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Net Income Before Extra. Items | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Total Extraordinary Items | 0 | ||||
Net Income | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Income Available to Common Excl. Extra. Items | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Income Available to Common Incl. Extra. Items | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Diluted Net Income | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Diluted Weighted Average Shares | 26.0133 | 26.0133 | 19.0319 | 29.1762 | 29.7185 |
Diluted EPS Excluding Extraordinary Items | -0.47034 | -0.4796 | -1.94305 | -2.63396 | -3.02657 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -0.47034 | -0.4796 | -1.94305 | -2.63396 | -3.02657 |
Other, Net | -0.247 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 23.313 | 21.783 | 21.677 | 23.544 | 21.863 |
Selling/General/Admin. Expenses, Total | 6.489 | 7.064 | 7.639 | 8.331 | 9.106 |
Research & Development | 16.824 | 14.719 | 14.038 | 15.213 | 12.757 |
Operating Income | -23.313 | -21.783 | -21.677 | -23.544 | -21.863 |
Interest Income (Expense), Net Non-Operating | 0.227 | 0.16 | 0.128 | 0.105 | 0.072 |
Net Income Before Taxes | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Net Income After Taxes | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Net Income Before Extra. Items | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Net Income | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Income Available to Common Excl. Extra. Items | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Income Available to Common Incl. Extra. Items | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Diluted Net Income | -23.086 | -21.754 | -21.706 | -23.399 | -21.641 |
Diluted Weighted Average Shares | 29.5549 | 29.5874 | 29.7674 | 29.962 | 30.1345 |
Diluted EPS Excluding Extraordinary Items | -0.78112 | -0.73525 | -0.72919 | -0.78095 | -0.71815 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.78112 | -0.73525 | -0.72919 | -0.78095 | -0.71815 |
Other, Net | -0.131 | -0.157 | 0.04 | 0.15 |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total Current Assets | 7.537 | 72.584 | 106.056 | 137.862 | 111.673 |
Cash and Short Term Investments | 7.343 | 71.716 | 99.864 | 133.82 | 106.802 |
Cash | 7.343 | 11.259 | 4.074 | 35.69 | 40.27 |
Cash & Equivalents | 0 | 11.815 | 46.155 | 16.151 | 15.954 |
Short Term Investments | 0 | 48.642 | 49.635 | 81.979 | 50.578 |
Prepaid Expenses | 0.141 | 0.766 | 5.504 | 3.348 | 3.376 |
Other Current Assets, Total | 0.053 | 0.102 | 0.688 | 0.694 | 1.495 |
Total Assets | 7.718 | 72.877 | 124.37 | 189.466 | 133.228 |
Property/Plant/Equipment, Total - Net | 0.122 | 0.283 | 1.334 | 1.101 | 1.428 |
Property/Plant/Equipment, Total - Gross | 0.166 | 0.378 | 1.617 | 1.716 | 2.387 |
Accumulated Depreciation, Total | -0.044 | -0.095 | -0.283 | -0.615 | -0.959 |
Other Long Term Assets, Total | 0.059 | 0.01 | 0.217 | 0.039 | 0.194 |
Total Current Liabilities | 1.763 | 1.457 | 8.892 | 16.996 | 14.222 |
Accounts Payable | 0.517 | 0.495 | 3.075 | 3.555 | 4.911 |
Accrued Expenses | 1.246 | 0.962 | 5.817 | 13.441 | 9.311 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10.82 | 1.457 | 8.892 | 17.204 | 14.642 |
Total Long Term Debt | 7.171 | 0 | 0 | 0 | 0 |
Long Term Debt | 7.171 | 0 | |||
Other Liabilities, Total | 1.886 | 0 | 0.208 | 0.42 | |
Total Equity | -3.102 | 71.42 | 115.478 | 172.262 | 118.586 |
Redeemable Preferred Stock | 17.178 | 104.046 | 0 | ||
Common Stock | 0.009 | 0.009 | 0.027 | 0.029 | 0.03 |
Additional Paid-In Capital | 0.06 | 0.239 | 185.196 | 318.574 | 355.234 |
Retained Earnings (Accumulated Deficit) | -20.349 | -32.825 | -69.805 | -146.654 | -236.599 |
Other Equity, Total | 0 | -0.049 | 0.06 | 0.313 | -0.079 |
Total Liabilities & Shareholders’ Equity | 7.718 | 72.877 | 124.37 | 189.466 | 133.228 |
Total Common Shares Outstanding | 26.0133 | 26.0133 | 26.8694 | 29.5432 | 30.0744 |
Long Term Investments | 16.763 | 50.464 | 19.933 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 149.885 | 135.843 | 119.427 | 111.673 | 96.353 |
Cash and Short Term Investments | 147.035 | 129.95 | 114.412 | 106.802 | 91.524 |
Cash | 24.569 | 5.744 | 8.357 | 40.27 | 27.403 |
Cash & Equivalents | 38.246 | 47.049 | 36.6 | 15.954 | 32.361 |
Short Term Investments | 84.22 | 77.157 | 69.455 | 50.578 | 31.76 |
Prepaid Expenses | 2.293 | 5.455 | 4.52 | 3.376 | 2.784 |
Other Current Assets, Total | 0.557 | 0.438 | 0.495 | 1.495 | 2.045 |
Total Assets | 174.522 | 161.39 | 147.416 | 133.228 | 116.13 |
Property/Plant/Equipment, Total - Net | 0.878 | 1.886 | 1.655 | 1.428 | 0.573 |
Property/Plant/Equipment, Total - Gross | 1.579 | 2.674 | 2.53 | 2.387 | 1.569 |
Accumulated Depreciation, Total | -0.701 | -0.788 | -0.875 | -0.959 | -0.996 |
Long Term Investments | 23.72 | 23.516 | 26.141 | 19.933 | 19.175 |
Other Long Term Assets, Total | 0.039 | 0.145 | 0.193 | 0.194 | 0.029 |
Total Current Liabilities | 17.867 | 18.537 | 14.154 | 14.222 | 9.71 |
Accounts Payable | 2.845 | 7.193 | 2.88 | 4.911 | 3.731 |
Accrued Expenses | 15.022 | 11.344 | 11.274 | 9.311 | 5.979 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18.038 | 19.31 | 14.764 | 14.642 | 9.75 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.171 | 0.773 | 0.61 | 0.42 | 0.04 |
Total Equity | 156.484 | 142.08 | 132.652 | 118.586 | 106.38 |
Common Stock | 0.029 | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-In Capital | 326.006 | 333.427 | 345.751 | 355.234 | 365.096 |
Retained Earnings (Accumulated Deficit) | -169.74 | -191.494 | -213.2 | -236.599 | -258.24 |
Other Equity, Total | 0.189 | 0.117 | 0.071 | -0.079 | -0.506 |
Total Liabilities & Shareholders’ Equity | 174.522 | 161.39 | 147.416 | 133.228 | 116.13 |
Total Common Shares Outstanding | 29.5759 | 29.6558 | 29.8673 | 30.0744 | 30.1496 |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -12.235 | -12.476 | -36.98 | -76.849 | -89.945 |
Cash From Operating Activities | -9.827 | -11.695 | -33.277 | -50.818 | -62.932 |
Cash From Operating Activities | 0.045 | 0.051 | 0.188 | 0.332 | 0.344 |
Non-Cash Items | 1.903 | 1.12 | 1.611 | 15.472 | 30.93 |
Cash Interest Paid | 0.001 | 0.001 | |||
Changes in Working Capital | 0.46 | -0.39 | 1.904 | 10.227 | -4.261 |
Cash From Investing Activities | -0.077 | -46.754 | -17.747 | -52.431 | 58.952 |
Capital Expenditures | -0.077 | -0.212 | -0.055 | -0.052 | -0.18 |
Other Investing Cash Flow Items, Total | 0 | -46.542 | -17.692 | -52.379 | 59.132 |
Cash From Financing Activities | 7.75 | 75.928 | 77.366 | 118.876 | 6.808 |
Issuance (Retirement) of Stock, Net | 0 | 75.678 | 77.925 | 118.91 | 6.808 |
Issuance (Retirement) of Debt, Net | 7.75 | 0.25 | -0.559 | -0.034 | 0 |
Net Change in Cash | -2.154 | 17.479 | 26.342 | 15.627 | 2.883 |
Foreign Exchange Effects | 0.055 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -23.086 | -44.84 | -66.546 | -89.945 | -21.641 |
Cash From Operating Activities | -13.61 | -31.172 | -48.514 | -62.932 | -16.091 |
Cash From Operating Activities | 0.086 | 0.173 | 0.26 | 0.344 | 0.038 |
Non-Cash Items | 7.285 | 14.371 | 22.238 | 30.93 | 9.375 |
Changes in Working Capital | 2.105 | -0.876 | -4.466 | -4.261 | -3.863 |
Cash From Investing Activities | 31.643 | 37.267 | 38.033 | 58.952 | 13.413 |
Capital Expenditures | -0.037 | -0.136 | -0.136 | -0.18 | -0.005 |
Other Investing Cash Flow Items, Total | 31.68 | 37.403 | 38.169 | 59.132 | 13.418 |
Cash From Financing Activities | 0.441 | 1.113 | 5.818 | 6.808 | 0.622 |
Issuance (Retirement) of Stock, Net | 0.441 | 1.113 | 5.818 | 6.808 | 0.622 |
Net Change in Cash | 18.474 | 7.208 | -4.634 | 2.883 | -2.16 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Foreign Exchange Effects | 0.029 | 0.055 | -0.104 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Lamond (David A.) | Individual Investor | 10.1955 | 3683658 | 1634720 | 2022-01-31 | |
EPIQ Capital Group, LLC | Investment Advisor | 5.6924 | 2056669 | -1218879 | 2022-09-30 | LOW |
Dominy (Stephen S) | Individual Investor | 3.9791 | 1437674 | 763 | 2022-01-31 | |
Lynch (Casey C) | Individual Investor | 3.2676 | 1180580 | -120000 | 2022-01-31 | |
Two Sigma Investments, LP | Hedge Fund | 2.6494 | 957229 | -63818 | 2022-09-30 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.4135 | 872006 | 84018 | 2022-09-30 | LOW |
Pfizer Inc | Corporation | 1.6607 | 600000 | -1456377 | 2021-12-31 | MED |
Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 1.4255 | 515041 | -13523 | 2022-09-30 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.3779 | 497835 | 30092 | 2022-09-30 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.3536 | 489073 | 489073 | 2022-09-30 | MED |
Millennium Management LLC | Hedge Fund | 1.2676 | 457991 | 112582 | 2022-09-30 | HIGH |
Low (Philip S) | Individual Investor | 1.2602 | 455309 | 455309 | 2022-05-19 | |
Renaissance Technologies LLC | Hedge Fund | 0.9251 | 334225 | 54726 | 2022-09-30 | HIGH |
Pacific Heights Asset Management, LLC | Investment Advisor | 0.8995 | 325000 | 0 | 2022-09-30 | LOW |
Burleson & Company, LLC | Investment Advisor | 0.8412 | 303918 | 43769 | 2022-09-30 | LOW |
Thye (Dirk) | Individual Investor | 0.7775 | 280911 | 280911 | 2022-05-19 | |
Lowe (Christopher P) | Individual Investor | 0.7335 | 265000 | 175000 | 2022-03-03 | LOW |
J.P. Morgan Securities LLC | Research Firm | 0.6392 | 230937 | -334793 | 2022-09-30 | MED |
BNP Paribas Securities Corp. North America | Research Firm | 0.5737 | 207267 | -78256 | 2022-09-30 | MED |
Smith (Karen L) | Individual Investor | 0.5389 | 194690 | 194690 | 2022-05-19 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cortexyme Inc. Company profile
About Cortexyme Inc
Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
269 East Grand Ave
94080
Income Statement
- Annual
- Quarterly
News

Central Bank Week: Fed, BOE, and ECB meeting previews - USD, EUR, GBP, S&P 500
A lookahead at possible Fed, BOE, and ECB meeting outcomes and market reactions.
14:40, 31 January 2023
FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023
WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com